Cannabinoid

SAN DIEGO — Baseline cannabinoid use associated with the need for increased sedation among patients who underwent endoscopy with endoscopist-directed conscious sedation, according to research presented at Digestive Disease Week.

BOULDER, Colo. - In this video from the International Extreme Sports Medicine Congress, Pat Karns, MA, ATC, discussed the benefits of different cannabinoids for extreme sports athletes.

BOSTON — Patients with eczema are increasingly turning to over-the-counter cannabinoid products and physicians should be ready to discuss their benefits, according to a poster presented at the American Academy of Dermatology Annual Meeting.

Healio Psychiatry’s five most-viewed stories in December highlight the lack of evidence for prescription cannabinoids in treating psychiatric disorders, the FDA’s breakthrough designation for a device that may assess autism risk using a hair strand, and the effects of geography and race/ethnicity on late-life depression severity.

Available evidence does not sufficiently support prescription cannabinoids for treating psychiatric disorders, according to results of a review published in American Journal of Psychiatry.

Using real-world data, researchers identified patterns of use of medically dispensed cannabis in patients with inflammatory bowel disease, according to a poster presented at the ACG Annual Scientific Meeting.

Comprehensive knowledge of the vast array of products is necessary for rheumatologists whose patients desire to use cannabis to treat their condition, according to a presenter at the 2021 Congress of Clinical Rheumatology-West.

An international panel of experts reported that non-inhaled medical cannabis or cannabinoids were associated with modest benefits in patients with chronic pain.

Recent cannabis users were more likely to report inadequate sleep durations than individuals who did not recently use cannabis, according to researchers. The association appeared to be stronger in heavy cannabis users.

Cannabis, cannabis-derived products and synthetic cannabinoids may slightly decrease rheumatoid arthritis disease activity, according to a meta-analysis published in the Journal of Clinical Rheumatology.